P302 RETENTION ON TREATMENT WITH LUMIRACOXIB IN PATIENTS WITH OSTEOARTHRITIS  by Fleischmann, R. et al.
Osteoarthritis and Cartilage Vol. 14, Supplement B S165
than men (75.5% vs 57.7%) and through randomisation got
their preference more often (48.7% vs. 26.7%, p 0.04). The
effects of patient preference on outcome was similar in men
and women, furthermore the overall results of this study were
independent of gender. Patients who had previously received an
IS were more likely to express a preference (83.1% vs. 60.4%,
p=0.003), but were less likely to receive it (32.7% vs. 50.9%,
p=0.002). Adjusting for previous intra-articular injections did not
significantly affect the overall results.
Conclusions: In this study, which demonstrated significant im-
provements for TI compared to IS, patient preference was also
a strong independent predictor of outcome. Those who did not
express a treatment preference obtained the best outcome and
those did not receive their preference did not benefit from the
treatments given. Previous studies suggesting that patient pref-
erence influences outcome have been conducted on treatments
with long term therapies and as such differences have been
attributed to adherence with treatment. This study of a single
baseline intervention suggests that compliance is not the only
reason and hence these findings have major implications for
clinical practice and for the design of future RCT’s.
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Purpose: Retention on treatment reflects the interrelated issues
of efficacy, safety and tolerability in OA patients. Objective: To
show that lumiracoxib 100 mg od and 100 mg bid are non-inferior
to celecoxib 200 mg od with respect to the retention rate at week
52 in patients with OA.
P302 – Table 1
Population treatment group N Retention rate Contrasts Estimated 97.5% CI Outcome
n (%) difference of difference
ITT
LUM 100mg od 755 354 (46.9) LUM 100mg od - CEL 200mg od 0.02 -0.04, 0.07 Non-inferiority shown
LUM 100mg bid 1519 722 (47.5) LUM 100mg bid - CEL 200mg od 0.02 -0.03, 0.07 Non-inferiority shown
CEL 200mg od 758 343 (45.3)
LUM = lumiracoxib; CEL = celecoxib.
Methods: In this 52 week, randomized, double-blind trial, 3036
patients with OA of the hip, knee, hand or spine were ran-
domized to lumiracoxib 100 mg od, lumiracoxib 100 mg bid (2x
recommended dose for OA) and celecoxib 200 mg od in a 1:2:1
ratio.
The primary efficacy variable was the retention rate at 52 weeks.
Non-inferiority was tested by comparing pairwise differences in
retention rates using a multiple testing procedure to adjust for
multiplicity and a confidence interval approach with a pre-defined
non-inferiority margin of -0.1. Secondary variables included effi-
cacy using patient’s assessment of OA pain intensity in the target
joint, patient’s and physician’s global assessment of disease ac-
tivity (defined as improvement by at least one grade in the Likert
scale), usage of rescue medication and safety and tolerability.
Results: Patient disposition was similar across the treatment
groups. Approximately 45% of patients in each group remained
on treatment until study end. An amendment to the protocol
following the announcement of possible increased CV risk with
celecoxib excluded patients with CCV history and elevated CV
risk (13%) and led to withdrawal of consent in 4% of the patients.
Other major reasons for discontinuations were adverse events
(12%), unsatisfactory therapeutic effect (11%) and withdrawal of
consent (7%).
The results of the retention to treatment analysis are shown in
Table 1.
Comparisons using an integrated measure of the overall level
of OA pain intensity and patient’s and physician’s global as-
sessments of disease activity showed no statistical significant
differences between treatment groups.
Improvement rates at study end for OA pain intensity (51 - 54%),
patient’s and physican’s global assessment and use of rescue
medication were comparable between the treatment goups.
The safety and tolerability of both lumiracoxib doses and cele-
coxib were generally similar, with comparable overall incidences
of AEs and SAEs. APTC events (stroke, MI, CV death) occurred
in similar rates (0.7-0.8%). ALT/AST elevations > 3 x ULN oc-
curred at a higher frequency in patients treated with lumiracoxib
100 mg bid (2x recommended dose) than with lumiracoxib 100
mg od or celecoxib 200 mg od.
Conclusions: Retention on treatment at 1 year of lumiracoxib
100mg od was non-inferior to celecoxib 200 mg od and all
secondary efficacy parameters were comparable between these
treatment groups. Lumiracoxib 100 mg od was shown to be as
effective and safe as celecoxib 200 mg od.
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Purpose: This trial is a prospective assessment of the effi-
cacy and tolerability of intra-articular sodium hyaluronate (SH;
